The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Merck Foundation ( the philanthropic arm of Merck KGaA Germany, conducted the 12th Edition of their annual conference, “Merck ...

In the latest trading session, Merck (MRK) closed at $111.11, marking a +1.52% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 1.16%. Elsewhere, the ...

Merck Foundation ( the philanthropic arm of Merck KGaA, Germany, in partnership with African and Asian First Ladies, released ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths ...

Moderna (MRNA) stock is in focus as the mRNA-based cancer drug with Merck's (MRK) Keytruda cut melanoma recurrence/death risk ...

MERCK is in talks to buy cancer drug developer Revolution Medicines in a $28-billion to $32-billion deal, the Financial Times ...

Moderna & Merck announce 5-year data for intismeran autogene in combo with Keytruda demonstrated sustained improvement in primary endpoint of recurrence-free survival in patients with high-risk stage ...

USA-based mRNA vaccines company Moderna’s shares were flat in pre-market activity, as the company announced awaited new ...